CTI BioPharma Corp. (NASDAQ:CTIC)

CAPS Rating: 2 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Results 1 - 20 of 55 : 1 2 3 Next »

Recs

0
Member Avatar clangmead (29.32) Submitted: 3/23/2015 8:15:32 AM : Outperform Start Price: $1.98 CTIC Score: -1.59

mpor1

Recs

0
Member Avatar pchop12316 (60.95) Submitted: 3/18/2015 1:15:27 PM : Outperform Start Price: $1.89 CTIC Score: +1.20

prospective successes appear very solid

Recs

1
Member Avatar zzlangerhans (99.81) Submitted: 3/18/2015 12:58:44 PM : Outperform Start Price: $1.90 CTIC Score: +1.04

Cell Therapeutics still isn't getting much love from commentators, but the difference now is that the company has to be acknowledged as a genuine developmental biotech. The relative success of pacritinib makes it harder to dismiss the prospects of Opaxio and tosedostat. Pacritinib may not be Jakafi, but Cell Therapeutics' 330M market cap isn't Incyte's 16B either. The stock may bleed out a little more, but I do see potential for a rebound here as the pipeline continues to mature.

Recs

0
Member Avatar derbydog85 (44.01) Submitted: 3/10/2015 1:45:41 AM : Outperform Start Price: $2.71 CTIC Score: -30.07

Just released positive data from a phase 3 trial. The drug treats bone marrow cancer (Pacritinib)

Recs

0
Member Avatar afrisque61 (< 20) Submitted: 2/15/2015 4:33:38 PM : Outperform Start Price: $2.21 CTIC Score: -12.39

Once a high-flyer, potentially poised for growth due to new product development.

Recs

2
Member Avatar kyawam (< 20) Submitted: 1/15/2014 12:52:43 AM : Outperform Start Price: $3.04 CTIC Score: -50.49

The company has been developing the drugs in their niche area for a while, having got partnership with Baxter to develop and commercialize for one of their drugs is a form of certification that the drugs is credible and have commercial potential. Some more recent unfreezing of FDA to continue one of their trial is also another good news for investor.

Recs

0
Member Avatar Jibo999 (< 20) Submitted: 1/7/2014 4:21:43 PM : Outperform Start Price: $2.36 CTIC Score: -32.32

CTI is performing extremely well for the last few moth. The stock has lots of potential for grow.

Recs

0
Member Avatar FULAWRENCEI (38.77) Submitted: 10/8/2013 8:03:04 AM : Outperform Start Price: $1.90 CTIC Score: -23.28

Super high interest, I get a kick out of people saying the company diluted shares when in fact the company reduced the number of shares by reverse splits 4 times!

Recs

0
Member Avatar ImFive (32.16) Submitted: 10/6/2013 11:11:07 PM : Outperform Start Price: $1.69 CTIC Score: -10.44

woah oh, livin' on a prayer

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:26:05 PM : Underperform Start Price: $1.08 CTIC Score: -56.39

CTIC Short. Biotech. No revenues, just issues more and more stock. Reminds me of china crescent.

Recs

0
Member Avatar bIlluminati (30.09) Submitted: 7/2/2013 2:45:48 PM : Underperform Start Price: $1.00 CTIC Score: -63.36

No profits.

Recs

0
Member Avatar Allstar13913 (99.83) Submitted: 4/27/2013 10:11:59 PM : Underperform Start Price: $1.18 CTIC Score: -32.71

Worthless Biopharm company. Has a drug twice rejected by the FDA but was approved for European use. AVOID.

Recs

0
Member Avatar aaronleetx (< 20) Submitted: 1/8/2013 5:18:56 PM : Outperform Start Price: $1.55 CTIC Score: -18.64

I think you guys will be awsome!!!!:D

Recs

0
Member Avatar OBAMABB (< 20) Submitted: 6/26/2012 7:10:59 PM : Outperform Start Price: $2.95 CTIC Score: -93.39

Keep Bashing CTIC 65 times in 6 months means you are trying to manipulate the stock your buddies must be real short!

Recs

0
Member Avatar bobleelaw (42.35) Submitted: 6/22/2012 7:02:32 PM : Outperform Start Price: $3.10 CTIC Score: -97.05

Cell Therapeutics, Inc. (CTIC)
Is well undervalued for what it has in the pipeline. This stock will be 100+% investor return in the next 6 months. I am not sure why it is not getting the attention it should, but that is fine by me as I accumulate shares on the cheap.

Recs

0
Member Avatar liken22 (< 20) Submitted: 1/30/2012 10:59:47 AM : Outperform Start Price: $5.41 CTIC Score: -125.62

Hit the lowest cap in a long time, so I think will go up

Recs

0
Member Avatar tommywaaf (< 20) Submitted: 1/26/2012 5:14:28 PM : Outperform Start Price: $6.75 CTIC Score: -132.23

Euro possible apporval in mid feb. Could bring interest

Recs

0
Member Avatar ltgenspecific (< 20) Submitted: 6/14/2010 5:44:12 PM : Outperform Start Price: $14.94 CTIC Score: -151.15

going with the gut, something's bound to give, Pixuvri seems to be somewhat effective... risky but if it takes, it'll run

Recs

0
Member Avatar libertybrewcity (< 20) Submitted: 9/3/2009 12:59:57 AM : Outperform Start Price: $45.90 CTIC Score: -207.55

The new drug is about to go into phase 3 and the stock will explode!

Recs

3
Member Avatar dbbfool63 (22.93) Submitted: 8/27/2009 6:28:48 PM : Outperform Start Price: $47.70 CTIC Score: -199.92

Good entry point for mid to long term.

I couldn't get in until it got above a dollar to rate it although been watching since .o7/shr.

Probably could of got in lower, but lost track watching others.

Results 1 - 20 of 55 : 1 2 3 Next »

Featured Broker Partners


Advertisement